Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
464 stopped studies mapped to Malignant Central Nervous System Neoplasm and descendants · 90% state a reason
Over the 464 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04629209 | A Phase II, Open Label Study of ONC201 in Adults With EGFR-low Glioblastoma | Phase 2 | withdrawn | Nov 16, 2020 | Masonic Cancer Center, University of Minnesota | Change in approach to study. | Other (stated, no rule matched) |
| NCT02432417 | The Addition of Chloroquine to Chemoradiation for Glioblastoma, | Phase 2 | withdrawn | May 4, 2015 | Maastricht Radiation Oncology | The study was withdrawn due to a lack of funding. The researchers were unable to secure the… | Funding |
| NCT02530502 | Radiation Therapy With Temozolomide and Pembrolizumab in Treating Patients With Newly… | Phase 1 | terminated | Aug 21, 2015 | Northwestern University | The protocol was amendment to be stopped after phase I (phase 2 removed from protocol) | Other (stated, no rule matched) |
| NCT04763031 | Recurrent GBM With Maximal Neurosurgical Removal and Treatment With IORT | N/A | terminated | Feb 21, 2021 | Parkridge Medical Center | No potential patients enrolled since first enrollment on 06/27/2022. | Enrollment / accrual |
| NCT03939858 | Bioenergetic Profiling and Cognition in GBM Patients | — | terminated | May 7, 2019 | Wake Forest University Health Sciences | Funding and laboratory access issues, study is closed | Funding |
| NCT02833701 | Bevacizumab and Ascorbic Acid in Patients Treating With Recurrent High Grade Glioma | Phase 1 | terminated | Jul 14, 2016 | University of Nebraska | not stated | Not stated |
| NCT03190967 | T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of… | Phase 1 / Phase 2 | terminated | Jun 19, 2017 | National Cancer Institute (NCI) | The phase II portion was never started as we could no longer get the drug from the manufacturer. | Drug supply |
| NCT02659800 | Study of the Effect NT-I7 on CD4 Counts in Patients With High Grade Gliomas | Phase 1 | terminated | Jan 20, 2016 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Terminated \[NCI decided to terminate ABTC Consortium due to NCI moving in different direction for… | Other (stated, no rule matched) |
| NCT03593993 | A Biospecimen Collection Study in BRAF-V600E Mutated Recurrent Gliomas | — | terminated | Jul 20, 2018 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | low accrual and lack of funds | Enrollment / accrual |
| NCT03971734 | Determining Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the… | Phase 1 | terminated | Jun 3, 2019 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Terminated \[NCI decided to terminate ABTC Consortium due to NCI moving in different direction for… | Other (stated, no rule matched) |
| NCT04167618 | 177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma | Phase 1 / Phase 2 | terminated | Nov 19, 2019 | Y-mAbs Therapeutics | Business priorities | Sponsor / business decision |
| NCT05054400 | Study of Laser Interstitial Thermal Therapy (LITT) Treatment Response Assessment With… | Early Phase 1 | withdrawn | Sep 23, 2021 | M.D. Anderson Cancer Center | 0 participant accrual | Enrollment / accrual |
| NCT04427228 | Single vs Multi-fraction SRS Patients on Immunotherapy(MIGRAINE) | Phase 2 | withdrawn | Jun 11, 2020 | University of Chicago | unable to enroll | Enrollment / accrual |
| NCT04608812 | Convection-enhanced Delivery of OS2966 for Patients With High-grade Glioma Undergoing a… | Phase 1 | terminated | Oct 29, 2020 | OncoSynergy, Inc. | Slow enrollment and financial constraints. | Enrollment / accrual |
| NCT04541225 | Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid… | Phase 1 | terminated | Sep 9, 2020 | Nuvation Bio Inc. | Sponsor decision | Sponsor / business decision |
| NCT05063357 | 131I-omburtamab Delivered by Convection-Enhanced Delivery in Patients With Diffuse… | Phase 1 | withdrawn | Oct 1, 2021 | Y-mAbs Therapeutics | Corporate business decision. Not due to safety or efficacy concerns. | Safety / toxicity |
| NCT04650204 | Perampanel for the Reduction of Seizure Frequency in Patients With High-grade Glioma and… | Phase 4 | terminated | Dec 2, 2020 | Mayo Clinic | The funding sponsor, EISAI, sold the US rights to the medication and can no longer provide it to… | Funding |
| NCT05242146 | GB5121 in Adult Patients With Relapsed/Refractory CNS Lymphoma(STAR CNS) | Phase 1 | terminated | Feb 16, 2022 | GB005, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. | Sponsor decision | Sponsor / business decision |
| NCT03332355 | Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies -… | Phase 1 | terminated | Nov 6, 2017 | Vanquish Oncology, Inc. | Business Reasons | Sponsor / business decision |
| NCT01721577 | Phase I/II Trial of AXL1717 in the Treatment of Recurrent Malignant Astrocytomas(AXL1717) | Phase 1 / Phase 2 | terminated | Nov 5, 2012 | Rush University Medical Center | Investigator went to another institution. | Investigator |
| NCT04741984 | Monocyte Antigen Carrier Cells for Newly Diagnosed GBM(DEMAND) | Phase 1 | withdrawn | Feb 5, 2021 | Michael Gunn | Due to need to proceed with procedural changes with goals of improving the technical and economic… | Other (stated, no rule matched) |
| NCT03055208 | Early Stereotactic Gamma Knife Radiosurgery to Residual Tumor After Surgery of Newly…(Gamma-GBM) | N/A | suspended | Feb 16, 2017 | Universitätsmedizin Mannheim | suspended due to low accrual rates | Enrollment / accrual |
| NCT05590273 | Forgotten Voices: Addressing Unmet Needs in Brain Tumor Caregivers(AIM 2) | N/A | terminated | Oct 21, 2022 | Virginia Commonwealth University | Insufficient caregiver participation | Other (stated, no rule matched) |
| NCT05410301 | Golden Halo, Static Magnetic and Electric Field Device, in Recurrent Glioblastoma | N/A | withdrawn | Jun 8, 2022 | Varun Monga, MD | PI leaving institution | Other (stated, no rule matched) |
| NCT03714334 | DNX-2440 Oncolytic Adenovirus for Recurrent Glioblastoma | Phase 1 | terminated | Oct 22, 2018 | Clinica Universidad de Navarra, Universidad de Navarra | Break of stock | Other (stated, no rule matched) |
| NCT04730349 | A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in…(PIVOT IO 020) | Phase 1 / Phase 2 | terminated | Jan 29, 2021 | Bristol-Myers Squibb | Business objectives have changed | Sponsor / business decision |
| NCT03956706 | Study of Stereotactic Radiosurgery to the Subventricular Zone in Malignant Gliomas | N/A | withdrawn | May 21, 2019 | Northwell Health | no partipants enrolled and investigator left the institution | Investigator |
| NCT01933815 | Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same… | Phase 1 / Phase 2 | suspended | Sep 2, 2013 | Cortice Biosciences, Inc. | Business reasons | Sponsor / business decision |
| NCT01700569 | Phase-1 Study of Folinic Acid to Modulate MGMT Gene in Glioblastoma(FOLAGLI) | Phase 1 | terminated | Oct 4, 2012 | Institut Cancerologie de l'Ouest | changing the standard of care | Other (stated, no rule matched) |
| NCT02664363 | EGFRvIII CAR T Cells for Newly-Diagnosed WHO Grade IV Malignant Glioma(ExCeL) | Phase 1 | terminated | Jan 27, 2016 | Daniel Landi | Study funding ended | Funding |
| NCT03430791 | Trial of Combination Tumor Treating Fields (TTF; Optune), Nivolumab Plus/Minus Ipilimumab… | Phase 2 | terminated | Feb 13, 2018 | Baptist Health South Florida | Study Investigator/Sponsor decided to end enrollment earlier. | Investigator |
| NCT01986348 | Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Participants With…(KING) | Phase 2 | terminated | Nov 18, 2013 | Karyopharm Therapeutics Inc | Study was terminated due to Sponsor decision (all except 1 patient were off-treatment and 2… | Sponsor / business decision |
| NCT02769806 | Advanced Perfusion MRI of Treatment Response and Progression in Glioblastoma | — | terminated | May 12, 2016 | University of Wisconsin, Madison | funding | Funding |
| NCT01822275 | Phase II Trial of Low-Dose Whole Brain Radiotherapy With Concurrent Temozolomide and…(GCC 1224) | Phase 2 | terminated | Apr 2, 2013 | University of Maryland, Baltimore | Poor accrual | Enrollment / accrual |
| NCT03119064 | BrUOG 329 Onivyde & Metronomic Temozolomide in Recurrent Glioblastoma(329) | Phase 1 / Phase 2 | terminated | Apr 18, 2017 | Brown University | lack of response to study therapy | Other (stated, no rule matched) |
| NCT04895553 | Incidence of Intracranial Hemorrhage in Glioma Patients With Venous Thromboembolism… | — | terminated | May 20, 2021 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | lack of funds. Only 1 patient was enrolled | Enrollment / accrual |
| NCT05017610 | Inducing a Hypothyroxinemic State in Patients With Recurrent Glioblastoma or Gliosarcoma | Early Phase 1 | withdrawn | Aug 24, 2021 | Emory University | Per the PI-slow accrual | Enrollment / accrual |
| NCT04782609 | Study of Icapamespib (PU-AD) in Patients With Recurrent Malignant Glioma(Glio) | Phase 1 | terminated | Mar 4, 2021 | Samus Therapeutics, Inc. | Samus Therapeutics Company Closure | Sponsor / business decision |
| NCT01954576 | NovoTTF Therapy in Treating Patients With Recurrent Glioblastoma Multiforme | N/A | terminated | Oct 7, 2013 | University of Florida | Poor accrual; Avastin refractory patients not feasible given treatment paradigm in these patients. | Enrollment / accrual |
| NCT02880111 | Rates DMBT1 ( Glycoprotein) in Sputum of CF Patients With Pseudomonas Aeruginosa(DMBT1) | — | terminated | Aug 26, 2016 | University Hospital, Lille | only one patient was included | Other (stated, no rule matched) |
| NCT03649464 | Investigation of Oral OKN-007 in Recurrent High-grade Glioma Participants | Phase 1 / Phase 2 | withdrawn | Aug 28, 2018 | Oblato, Inc. | Planned to execute the new Oral OKN-007 clinical trial with modified study plan soon. This Study… | Other (stated, no rule matched) |
| NCT02885324 | Pilot Study of Cabozantinib for Recurrent or Progressive Central Nervous System Tumors in… | Phase 2 | terminated | Aug 31, 2016 | Indiana University | Failure to meet accrual goals. | Enrollment / accrual |
| NCT04776980 | Multimodality MRI and Liquid Biopsy in GBM | Early Phase 1 | withdrawn | Mar 2, 2021 | Abramson Cancer Center at Penn Medicine | PI decision to close study | Other (stated, no rule matched) |
| NCT04200066 | A Study of Maprotiline in Combination With Tamoxifen and Temozolomide for Recurrent… | Phase 1 | withdrawn | Dec 16, 2019 | University of Rochester | One of the drugs for the study is not commercially available. | Other (stated, no rule matched) |
| NCT03856099 | TTAC-0001 Phase II Trial With Recurrent Glioblastoma Progressed on Bevacizumab | Phase 2 | terminated | Feb 27, 2019 | PharmAbcine | Subject recruitment issues and follow-up study plans | Enrollment / accrual |
| NCT03022578 | Laser Interstitial Thermal Therapy and Lomustine in Treating Patients With Recurrent… | Phase 2 | terminated | Jan 16, 2017 | M.D. Anderson Cancer Center | Slow accrual | Enrollment / accrual |
| NCT04489420 | Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent…(CYNK001GBM01) | Phase 1 | terminated | Jul 28, 2020 | Celularity Incorporated | Business decision. | Sponsor / business decision |
| NCT04926168 | 6 Months Adjuvant Temozolomide (TMZ) vs No Adjuvant TMZ in Newly Diagnosed MGMT… | — | withdrawn | Jun 15, 2021 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | lack of funds | Funding |
| NCT01884740 | Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial… | Phase 1 / Phase 2 | terminated | Jun 24, 2013 | Weill Medical College of Cornell University | The study was prematurely closed in December 2021 due to low accrual. | Enrollment / accrual |
| NCT03727841 | Marizomib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial, and… | Phase 2 | terminated | Nov 1, 2018 | National Cancer Institute (NCI) | The pharmaceutical company decided to close their program evaluating the study agent, Marizomib. | Sponsor / business decision |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Nov 24, 2023source: clinicaltrials